Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data

Amgen and Novartis revealed the first set of Phase III data for a CGRP inhibitor in the treatment of episodic migraine, potentially positioning the companies’ biologic erenumab at the head of the drug class.

Four development programs are neck-and-neck in the race to bring a calcitonin gene-related peptide (CGRP) inhibitor to market, and Amgen Inc. is the first company – with its partner Novartis AG – to report positive Phase III results for their biologic erenumab (AMG 334) in episodic headache sufferers.

Speed of development is key, because Amgen and Novartis may have to be the first anti-CGRP developers to commercialize a...

More from Neurological

More from Therapy Areas

PureTech Ponders Way Forward As CEO Exits

 
• By 

Bharatt Chowrira departs days after firm’s chair stepped down.

Sun’s Alopecia Treatment Debuts In US - Can It Make Up For Lost Time?

 

Sun’s Leqselvi goes up against Lilly's Olumiant and Pfizer's Litfulo, which currently has the broadest label, in the US alopecia market. Can it shake things up early, amid growing activity in the space with several new mechanisms of action being investigated?

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.